Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Verinurad prolonged release HPMC capsule
Verinurad prolonged release HPMC · 1 trial · 1 indication
The AUCinf of verinurad, allopurinol and oxypurinol were assessed in fasted state as PK parameters
The AUClast of verinurad, allopurinol and oxypurinol were assessed in fasted condition as PK parameters
The Cmax of verinurad, allopurinol and oxypurinol were assessed in fasted state as PK parameters
| Arm | Type | Description |
|---|---|---|
| Treatment 1 | EXPERIMENTAL | Subjects will receive verinurad prolonged release HPMC capsule and allopurinol tablet in fasted state on Day 1. |
| Treatment 2 | EXPERIMENTAL | Subjects will receive verinurad/allopurinol FDC capsule in fasted state on Day 1. |
| Treatment 3 | EXPERIMENTAL | Subjects will receive verinurad/allopurinol FDC capsule in fed state on Day 1. |
| Treatment 4 | EXPERIMENTAL | Subjects will receive verinurad prolonged release HPMC capsule and allopurinol tablet in fed state on Day 1. |
| Treatment 5 | EXPERIMENTAL | Subjects will receive verinurad prolonged release gelatin capsule in fasted state on Day 1. |
| Name | Type | Description |
|---|---|---|
| Verinurad prolonged release HPMC capsule | DRUG | Randomized subjects will receive oral dose of verinurad HPMC capsule. |
| Allopurinol Tablet | DRUG | Randomized subjects will receive oral dose of allopurinol tablet. |
| Verinurad/Allopurinol FDC Capsule | DRUG | Randomized subjects will receive oral dose of Verinurad/Allopurinol FDC capsule. |
| Verinurad prolonged release gelatin Capsule | DRUG | Randomized subjects will receive oral dose of Verinurad gelatin capsule. |
Inclusion Criteria: * Provision of signed and dated, written informed consent prior to any study specific procedures. * Healthy male and female subjects aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venepuncture. * Have a body mass index between 18 and 30 kg/m\^2 (...
Top 20 of 28 competitors
Verinurad prolonged release HPMC is an investigational small molecule developed by AstraZeneca PLC (ticker AZN) for chronic kidney disease. It is a prolonged release capsule formulation of verinurad. The drug is in Phase 1 clinical development and has been studied in a single completed trial.
Verinurad prolonged release HPMC targets SLC22A12, also known as URAT1, and acts as an inhibitor of this transporter. SLC22A12 is involved in uric acid reabsorption in the kidney, and inhibiting it is the intended mechanism of action for this small molecule.
Verinurad prolonged release HPMC is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the clinical program evaluating this prolonged release capsule formulation in chronic kidney disease.
Verinurad prolonged release HPMC is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, and no trials are currently active.
Verinurad prolonged release HPMC has been evaluated in one completed Phase 1 trial, NCT04550234, titled a study in healthy subjects to assess drug availability of 4 different formulations of verinurad and allopurinol. The trial enrolled 25 participants in Germany and included a controlled, randomized design.
Yes, verinurad prolonged release HPMC capsule is another name for verinurad prolonged release HPMC. Both refer to the same AstraZeneca small molecule formulation being studied in chronic kidney disease, so searches using either name point to the same investigational asset.